Kairos Pharma, LTD. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Kairos Pharma amended its Purchase Agreement with Helena Global Investment Opportunities I Ltd. (dated Nov 12, 2024) three times between Feb–Oct 2026: (1) changed pricing from fixed to 97% of daily VWAP net of expenses; (2) shortened Pricing Period from 3 trading days to 1 trading day (Oct 26, 2026); (3) extended agreement termination from original 36-month anniversary to December 31, 2028 (Oct 29, 2026). No dollar amounts or share counts disclosed. Filing also includes Nov 2026 press release announcing interim Phase 2 data for ENV-105 in prostate cancer showing 17.7-month median PFS vs. 2 months comparator (p=0.0008).
Why this rating
PIPE amendments are ordinary for micro-cap biotech; multiple amendments suggest capital access concerns but no amounts disclosed. Clinical data positive but already public-facing. Moderate for $6.9M company.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.